IQV - IQVIA Holdings Inc.

NYSE - NYSE Delayed Price. Currency in USD
111.11
+0.86 (+0.78%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close110.25
Open110.08
Bid0.00 x 0
Ask0.00 x 0
Day's Range110.03 - 111.17
52 Week Range87.45 - 111.17
Volume1,364,024
Avg. Volume1,544,766
Market Cap22.479B
Beta0.67
PE Ratio (TTM)18.89
EPS (TTM)5.88
Earnings DateJul 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est117.94
Trade prices are not sourced from all markets
  • 3 Top Healthcare Stocks to Buy in July
    Motley Fool2 days ago

    3 Top Healthcare Stocks to Buy in July

    New products, bigger markets, and market-moving news could cause shares in these three companies to rally.

  • The Zacks Analyst Blog Highlights: WNS, IQVIA, WEX, Blucora and Black Knight
    Zacks5 days ago

    The Zacks Analyst Blog Highlights: WNS, IQVIA, WEX, Blucora and Black Knight

    The Zacks Analyst Blog Highlights: WNS, IQVIA, WEX, Blucora and Black Knight

  • ACCESSWIRE6 days ago

    Free Stock Performance Review on IQVIA Holdings and Three Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on IQV sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following Medical Laboratories and Research stocks for review this morning: iKang Healthcare Group Inc. (NASDAQ: KANG), Invitae Corp. (NYSE: NVTA), IQVIA Holdings Inc. (NYSE: IQV), and Laboratory Corp. of America Holdings (NYSE: LH).

  • Business Wire12 days ago

    IQVIA to Announce Second-Quarter 2018 Results on July 24, 2018

    IQVIA Holdings Inc. , will announce its second-quarter 2018 financial results before the market opens on Tuesday, July 24, 2018. The IQVIA management team will also host a conference call and webcast at 9:00 a.m.

  • IQVIA Holdings Inc (NYSE:IQV): Time For A Financial Health Check
    Simply Wall St.25 days ago

    IQVIA Holdings Inc (NYSE:IQV): Time For A Financial Health Check

    There are a number of reasons that attract investors towards large-cap companies such as IQVIA Holdings Inc (NYSE:IQV), with a market cap of US$20.40b. Market participants who are conscious ofRead More...

  • Should You Be Tempted To Buy IQVIA Holdings Inc (NYSE:IQV) At Its Current PE Ratio?
    Simply Wall St.last month

    Should You Be Tempted To Buy IQVIA Holdings Inc (NYSE:IQV) At Its Current PE Ratio?

    This article is intended for those of you who are at the beginning of your investing journey and want to better understand how you can grow your money by investingRead More...

  • Business Wirelast month

    IQVIA Launches a Transformative Suite of Virtual Research Solutions

    Powered by the IQVIA CORE™, Virtual Research Solutions brings together unparalleled information assets, advanced analytics, technologies and critical domain expertise to design and execute trials and late-phase studies with people in mind. The suite of solutions leverages IQVIA’s global resources and expertise in a secure, cloud-based platform designed to help accelerate research with a keen focus on protecting privacy and reducing risk. IQVIA’s Virtual Research Solutions is enabled by a range of complementary applications, including eConsent™ for online enrollment, AppScript™ to support digital patient engagement and the IQVIA Study Hub™, a virtual research technology platform designed to coordinate research and workflows, support patient communications, and seamlessly capture study activity throughout the patient journey.

  • Business Wirelast month

    IQVIA Announces Pricing of Secondary Public Offering

    IQVIA intends to repurchase from the underwriter 4,000,000 shares (the “Repurchase”). IQVIA is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering.

  • Business Wirelast month

    IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock

    IQVIA Holdings Inc. (“IQVIA”) (IQV) announced today the launch of an underwritten, secondary public offering of 12,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, and Dr. Dennis B. Gillings, CBE (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 4,000,000 shares (the “Repurchase”). IQVIA is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering.

  • Business Wirelast month

    IQVIA Announces Senior Secured Credit Facility Transaction to Refinance Existing Indebtedness

    USD term B loans of $950 million due 2025, priced at LIBOR plus a margin of 175 basis points, which represents a 25 basis point margin improvement compared to IQVIA Inc.’s existing USD term B loans. The EUR term B loans have a floor of 50 basis points, which represents a 25 basis point improvement compared to IQVIA Inc.’s existing EUR term B loans.

  • Business Wire2 months ago

    IQVIA Launches Commercial Content Management Solution IQVIA™ ePromo

    IQVIA  , a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, today announced the launch of IQVIA™ ePromo, a new cloud-based content management technology solution.

  • ACCESSWIRE2 months ago

    Free Stock Performance Review on Organovo Holdings and Three Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want a free Stock Review on ONVO sign up now at www.wallstequities.com/registration. Durham, North Carolina headquartered IQVIA Holdings Inc.'s stock finished Wednesday's session 1.31% higher at $100.48 with a total trading volume of 968,866 shares. Over the last month and the previous three months, the Company's shares have advanced 4.93% and 2.19%, respectively.

  • Investopedia2 months ago

    Five Favorites that Turn Data Into Dollars 

    If "The Graduate" were filmed today, the career advice to young Benjamin Braddock would likely be “data” rather than “plastics.” We turn to five leading stock experts and contributors to  MoneyShow.com for ways to invest in increased data use and storage. Demand for data storage continues to outpace supply, particularly as tech continues to push into new data-intensive areas such as artificial intelligence and augmented and virtual reality.

  • Moody's2 months ago

    IQVIA Inc. -- Moody's assigns Ba1 ratings to IQVIA's new senior secured credit facilities

    Moody's Investors Service, ("Moody's") assigned Ba1 ratings to the proposed senior secured credit facilities of IQVIA Inc. ("IQVIA"). There are no changes to IQVIA's existing ratings, including the Ba2 Corporate Family Rating, Ba2-PD Probability of Default Rating, and SGL-1 Speculative Grade Liquidity Rating.

  • Business Wire2 months ago

    IQVIA™ Institute for Human Data Science Study: Spending on Cancer Meds in the U.S. Doubled from 2012-2017 – Expected to Double Again by 2022 to $100 Billion

    The IQVIA™ Institute for Human Data Science found in its latest report, Global Oncology Trends 2018: Innovation, Expansion and Disruption, that spending on cancer drugs in the U.S. has doubled since 2012, reaching almost $50 billion in 2017, with two-thirds of the growth tied to drugs launched within the past five years. The study also showed wide differences in final out-of-pocket costs for U.S. patients paying for cancer medicines based on drug choice, manufacturer prices and insurance plans. “Payers continue to be challenged as they seek value and fund access to the latest oncologic treatment options,” said Murray Aitken, IQVIA senior vice president and executive director of the IQVIA Institute for Human Data Science.

  • Business Wire2 months ago

    PruGen Pharmaceuticals Selects IQVIA’s OCE Technology Platform to Advance Field Sales and Home Office Effectiveness

    IQVIA™ (IQV), a company dedicated to applying advanced analytics and technology to help healthcare clients find better solutions for patients, today announced that PruGen Pharmaceuticals has selected Orchestrated Customer Engagement (OCE), IQVIA’s next-generation commercial technology platform to help increase the efficiency and effectiveness of the company’s commercial teams. The innovative technology and superior usability built into the OCE platform, in addition to a high level of satisfaction with IQVIA as a long-standing collaborator, were primary decision-making factors for PruGen.

  • Business Wire2 months ago

    IQVIA Reaffirms Its Second-Quarter and Full-Year 2018 Guidance, Including Adjusted EPS Growth of 13.6% to 20.4% and 14.3% to 19.9%, Respectively

    IQVIA Holdings Inc. (“IQVIA”) (IQV), a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, today reaffirmed its second-quarter and full-year 2018 guidance previously provided on May 2nd. Specifically, for the second quarter, IQVIA reaffirms its guidance provided in the table below.

  • Business Wire2 months ago

    IQVIA Holdings Inc. Provides Update on Secondary Offering

    IQVIA Holdings Inc. , a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, announced today that in light of recent market conditions, it and the selling stockholders will not proceed with the previously announced secondary public offering and concurrent repurchase of common stock.

  • Reuters2 months ago

    FDA reports inaccuracy in IQVIA data on opioids

    The U.S. Food & Drug Administration on Wednesday said it found inaccuracies in information on opioid sales provided by healthcare data firm IQVIA Holdings Inc and called on the company to hire an independent auditor to review its data quality. The regulator said it found additional issues with IQVIA's information about other controlled substances. Shares of IQVIA were down 3.1 percent at $98.90, after falling as much as 10.3 percent earlier in the day.

  • Iqvia stock drops after FDA questions sales data
    American City Business Journals2 months ago

    Iqvia stock drops after FDA questions sales data

    Iqvia's stock dropped nearly 9 percent Wednesday after the U.S. Food and Drug Administration issued a statement questioning sales data from the company.

  • MarketWatch2 months ago

    IQVIA shares drop 4% after FDA raises 'serious concerns' with its data

    IQVIA Holdings Inc. shares dropped 4.5% in extremely heavy Wednesday afternoon trade before being halted on Wednesday after the Food and Drug Administration raised serious concerns with the company's data, which tracks the amount of pharmaceuticals sold in the U.S., and in particular data related to controlled substances like prescription fentanyl. While doing an analysis, the regulator said it discovered a more than 20% discrepancy between the amount of prescription fentanyl actually sold in the U.S. over the last five years and IQVIA's database. After conducting an investigation and speaking with the company, the FDA said that past prescription fentanyl data were overestimated because of an error in the company's methods, likely related to using the wrong conversion factors to figure out how much fentanyl is in a given unit.

  • Business Wire2 months ago

    IQVIA Response to FDA Statement

    IQVIA™ is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. We also provide a select set of services to the FDA and other government agencies.

  • Reuters2 months ago

    FDA finds inaccuracy in IQVIA sales data on some opioids

    The U.S. Food & Drug Administration said on Wednesday it discovered inaccuracies in sales data provided by IQVIA Holdings Inc, a vendor it contracts, regarding some opioid drug products. The regulator ...

  • Business Wire2 months ago

    IQVIA Announces Pricing of Secondary Public Offering

    IQVIA Holdings Inc. announced today the pricing of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, Leonard Green & Partners, L.P., and Dr.

  • Business Wire2 months ago

    IQVIA Announces Launch of Secondary Public Offering and Repurchase of Common Stock

    IQVIA Holdings Inc. (“IQVIA”) (IQV) announced today the launch of an underwritten, secondary public offering of 10,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc., investment funds associated with Bain Capital Investors, LLC, Leonard Green & Partners, L.P., and Dr. Dennis B. Gillings, CBE and certain of his affiliates (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,500,000 shares (the “Repurchase”). IQVIA is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering.